<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
RNAZ
Transcode Therapeutics
$
()


  • Transcode announces FDA clearance to initiate Phase 1/2 trial of TTX-MC138

    4/15/2024 - 09:03am
  • Transcode Therapeutics sees cash runway into late Q3/early 4Q24

    4/3/2024 - 09:12am
  • Transcode Therapeutics reports 2023 EPS ($103.61) vs. ($1,082.79) last year

    4/3/2024 - 09:11am
  • Transcode Therapeutics announces appointment of Vlock as CMO

    3/28/2024 - 08:39am
  • Transcode Therapeutics, Akribion report progress on CRISPR-derived tech

    3/11/2024 - 09:02am
  • Transcode Therapeutics reports publication of U.S. patent application

    2/20/2024 - 08:08am
  • Transcode regains compliance with Nasdaq stockholders' equity requirement

    1/31/2024 - 16:18pm
  • Transcode Therapeutics announces co-research agreement with Debiopharm

    1/29/2024 - 08:38am
  • Transcode Therapeutics Inc trading halted, news pending

    1/12/2024 - 19:50pm
  • Transcode Therapeutics CEO Michael Dudley resigns

    1/12/2024 - 16:08pm
  • Transcode Therapeutics files to sell 1.27M shares of common stock, warrants

    1/11/2024 - 08:25am
  • Transcode Therapeutics announces 1-for-40 reverse stock split

    1/11/2024 - 08:06am
  • Transcode Therapeutics publishes open letter to shareholders

    1/4/2024 - 08:47am
  • Transcode Therapeutics reports pre-clinical results with candidate TTX-MC138

    12/12/2023 - 08:35am
  • Transcode Therapeutics to present Phase 0 data at 2023 San Antonio symposium

    12/5/2023 - 09:17am
dynamic_feed Breaking News